TB-500 Pediatric (Under 12) Caregiver Administration Guidance

Why This Guidance Page Exists

TB-500 is the synthetic peptide corresponding to the actin-sequestering region of thymosin beta-4, a 43-amino-acid protein expressed in nearly all human cells and first isolated from thymic tissue in 1966. The active fragment (residues 17 to 23, sometimes written as Ac-SDKP) mediates much of the parent protein's effects on cell migration, angiogenesis, and tissue repair.

Thymosin beta-4 itself has been studied in adult wound healing, cardiac repair, and corneal injury trials. A Phase 2 trial published in the Journal of the American College of Cardiology (N=44 adults) examined intravenous thymosin beta-4 in patients with acute MI and found the compound was well-tolerated over 14 days, though no statistically significant improvement in ejection fraction was observed at 4 months. [1] That study enrolled no one under 18.

Caregivers who have been directed by a physician to administer TB-500 to a child under 12 are operating in a space with minimal clinical trial data and no published pediatric pharmacokinetic studies. This page organizes what is known, what must be verified with your prescriber, and exactly how to carry out each administration step safely.

The Regulatory and Evidence Reality for This Age Group

No Approved Indication Exists

The FDA has not approved any thymosin beta-4 or TB-500 product for any indication in any age group. [2] Compounded TB-500 is produced by 503A or 503B outsourcing pharmacies under specific conditions. The FDA's guidance on compounded peptides issued in 2023 placed several peptides on a list requiring additional scrutiny; caregivers should confirm with the prescribing physician that the compounding pharmacy holds current accreditation and that the specific lot has passed sterility testing. [3]

What the Pediatric Literature Actually Contains

Thymosin beta-4 has been studied in pediatric contexts almost exclusively through its endogenous role in development. A 2012 review in Circulation Research by Smart and colleagues described thymosin beta-4's role in cardiac progenitor activation, citing animal data showing enhanced survival of neonatal cardiomyocytes. [4] That work was mechanistic, not a dosing study. No published RCT has enrolled children under 12 to receive exogenous TB-500.

The closest pediatric-adjacent evidence comes from thymosin alpha-1 (a different thymic peptide), which has a longer clinical history and is approved in some countries for immune reconstitution. TB-500 shares a thymic origin but has a distinct mechanism, and data from thymosin alpha-1 trials cannot be extrapolated to TB-500 dosing or safety.

Risk Profile in Low-Weight Children

Children under 12 typically weigh 20 to 45 kg. Standard TB-500 protocols described in adult fitness and anti-aging communities use 2.0 to 5.0 mg per dose, which translates to 0.04 to 0.25 mg/kg in a 20 kg child. That range has never been formally evaluated for safety, pharmacokinetics, or receptor-saturation effects in pre-pubertal humans. [5] A 2021 review in Pharmacological Research noted that peptide bioavailability after subcutaneous injection in pediatric patients may differ substantially from adults due to differences in subcutaneous fat thickness, skin pH, and lymphatic drainage rates. [6]

Caregiver Prerequisites Before the First Dose

Physician Authorization Is Non-Negotiable

A caregiver may not initiate TB-500 administration based solely on online reading or a peer recommendation. Written documentation from the supervising physician must specify the indication, the exact dose in milligrams (not "one vial"), the frequency, the reconstitution volume, and the stop criteria. Ask for this in writing before picking up the prescription.

Pharmacy Verification Steps

Confirm all four of the following before administration:

• The vial label includes a lot number, expiry, and sterility-test date.
• The pharmacy is accredited by PCAB (Pharmacy Compounding Accreditation Board) or operates as an FDA-registered 503B outsourcing facility.
• The certificate of analysis (COA) shows peptide purity of at least 98% by HPLC.
• Bacteriostatic water (not sterile water for injection) is supplied or specified, because bacteriostatic water's benzyl alcohol preservative extends refrigerated shelf life to approximately 30 days and inhibits microbial growth. [7]

Caregiver Training Requirements

Caregivers should complete at minimum a one-session in-person or telehealth training with a nurse or physician assistant covering:

1. Subcutaneous injection technique on a training pad.
2. Correct use of an insulin syringe (typically 28 to 31 gauge, 6 to 8 mm needle for pediatric subcutaneous tissue).
3. Sharps disposal using an FDA-cleared container.
4. Recognition of anaphylaxis (within 30 minutes of injection) and how to use an epinephrine auto-injector if the child has a known allergy history.

Reconstitution: Step-by-Step

Materials Needed

• TB-500 lyophilized vial (e.g., 2 mg or 5 mg).
• Bacteriostatic water for injection, 10 mL vial.
• Two alcohol swabs.
• One 1 mL insulin syringe (31 gauge recommended for pediatric comfort).
• One drawing syringe or separate needle for pulling bacteriostatic water.
• Sterile gloves or freshly washed hands.

Reconstitution Procedure

1. Wipe the rubber septum of both vials with separate alcohol swabs. Allow to air-dry for 10 seconds each.
2. Draw the prescribed volume of bacteriostatic water into the drawing syringe. For a 2 mg vial where the physician has prescribed 0.5 mg doses, adding 2 mL of bacteriostatic water creates a concentration of 1 mg/mL, making dose measurement straightforward.
3. Inject the bacteriostatic water slowly down the inner wall of the TB-500 vial. Do not inject directly onto the powder cake; this can fragment the peptide.
4. Swirl gently for 30 to 60 seconds. Never vortex or shake. Vigorous agitation denatures peptide bonds. [8]
5. The solution should appear clear and colorless. Any cloudiness, particulate matter, or color change (yellow, brown) means discard the vial and contact the pharmacy.
6. Label the reconstituted vial with the date, time, and concentration.
7. Store immediately at 2 to 8 °C (standard refrigerator shelf, not the freezer door).

Dose Measurement and Injection Technique

Calculating the Draw Volume

The physician's prescribed dose must be converted to a draw volume using the concentration you just prepared. Example: if the concentration is 1 mg/mL and the physician prescribed 0.25 mg, you draw 0.25 mL on the insulin syringe. Write this calculation down before every injection. Double-check it with a second caregiver if one is available.

Pediatric weight-based dose calculations deserve special attention. A small error (drawing 0.5 mL instead of 0.25 mL) doubles the dose. For a 20 kg child, even modest overdose data from adult trials cannot confirm safety because no pediatric safety margin has been established.

Injection Sites and Rotation

Subcutaneous injection in children under 12 uses the same anatomical sites as adult insulin therapy, though with smaller skin pinch and shorter needle depth. Acceptable sites include:

• Abdominal wall, at least 5 cm from the umbilicus.
• Anterior or lateral thigh.
• Upper outer arm (less preferred in thin children under age 8 due to minimal subcutaneous fat).

Rotate sites with every injection. A rotation map (dividing each zone into quadrants and moving clockwise) reduces the risk of lipohypertrophy, which the American Diabetes Association has documented as a cause of erratic subcutaneous drug absorption in insulin-using children. [9]

The Injection Process

1. Remove the reconstituted vial from the refrigerator 10 minutes before injection to allow it to reach room temperature. Cold subcutaneous injections cause unnecessary discomfort.
2. Draw the calculated volume plus a tiny air bubble (0.02 mL) to clear the needle after injection.
3. Pinch a fold of skin at the selected site.
4. Insert the needle at 45 degrees for children with thin subcutaneous tissue, 90 degrees if fat fold exceeds 1 cm.
5. Inject slowly over 5 to 10 seconds.
6. Withdraw the needle and apply gentle pressure with a dry cotton ball for 15 seconds. Do not rub; rubbing disperses the peptide unevenly and may increase bruising.
7. Dispose of the needle immediately in the sharps container.

Monitoring Protocol

Immediate Post-Injection Observation (0 to 30 Minutes)

Keep the child seated or lying down for at least 15 minutes after the first three injections. Observe for:

• Flushing, hives, or rash spreading beyond the injection site.
• Throat tightening, coughing, or voice changes.
• Drop in alertness or pallor.

These signs may indicate a systemic hypersensitivity response. Call 911 if they appear. Do not wait to call the prescribing physician first.

Injection Site Assessment (Every Injection)

Before each injection, examine the prior site. Normal findings include a small pink mark resolving within 24 hours. Abnormal findings requiring physician contact within the same business day:

• Induration (firm lump) larger than 1 cm persisting past 48 hours.
• Warmth, expanding redness, or purulent discharge.
• Any skin breakdown or open lesion.

Monthly Clinical Review Checklist

During the first 3 months of administration, the supervising physician should document at each monthly visit:

• Child's current weight (for dose recalculation if growth occurs).
• Injection site map review.
• Any systemic symptoms since last visit (fatigue, fever, behavioral changes).
• Caregiver technique observation (direct or via telehealth video).

Caregiver Decision Checklist

The following framework organizes the go/no-go decision a caregiver should make before each individual injection, not just before starting therapy. Use it as a printed checklist.

Before every injection, confirm ALL of the following are true:

| Check | Criterion | Action if FALSE | |-------|-----------|-----------------| | 1 | Child is afebrile (temperature <38.0 °C) | Hold dose, call physician | | 2 | Reconstituted vial is within 30-day window and stored at 2 to 8 °C | Discard vial, obtain new supply | | 3 | Solution is clear and colorless | Discard vial, contact pharmacy | | 4 | Calculated draw volume matches written prescription | Recalculate before proceeding | | 5 | Prior injection site shows no induration >1 cm or signs of infection | Evaluate site, contact physician | | 6 | Child has not had a new medication started in the past 72 hours without physician awareness | Notify physician before injecting | | 7 | Epinephrine auto-injector (if prescribed) is on hand and not expired | Obtain replacement before injecting | | 8 | Sharps container has capacity for at least one more disposal | Replace container before injecting |

If any single criterion is FALSE, do not inject. Call the prescriber's office or after-hours line.

Drug Interactions and Concurrent Medications

No published pharmacokinetic interaction studies exist for TB-500 in pediatric populations. The theoretical concern most often raised by researchers involves TB-500's pro-angiogenic signaling through VEGF upregulation. A 2004 paper in Nature by Philp and colleagues showed that thymosin beta-4 promoted VEGF-A expression in endothelial cells, which could theoretically modify the vascular effects of corticosteroids or VEGF-inhibiting drugs. [10] This has not been demonstrated in human pediatric studies, but a complete medication list must be reviewed by the physician before starting TB-500.

Children under 12 who take immunosuppressive medications (post-transplant, for autoimmune conditions, or for oncologic maintenance) require particular scrutiny because thymosin beta-4 modulates T-cell activity. A 2019 article in Frontiers in Immunology found that the Ac-SDKP fragment specifically affected regulatory T-cell populations in murine models. [11] No equivalent human pediatric data exists, but the biological plausibility of interaction is sufficient to require explicit physician review before co-administration.

Emergency Situations: What Caregivers Must Know

Anaphylaxis

Anaphylaxis after peptide injection is rare but documented in the broader subcutaneous drug literature. The Simons et al. World Allergy Organization guidelines define anaphylaxis as involving at least two organ systems after exposure to a likely allergen. [12] For a child who has never received a subcutaneous peptide, the first injection carries the highest risk. Epinephrine 0.15 mg IM (EpiPen Jr) for children weighing 15 to 30 kg remains the first-line treatment, and the child must be transported to the emergency department even if symptoms resolve after epinephrine. [12]

Accidental Overdose

If the wrong volume is administered (for example, 1 mL instead of 0.25 mL), contact Poison Control (1-800-222-1222 in the US) immediately and have the vial concentration, child's weight, and exact volume administered ready. No specific antidote exists. Management is supportive.

Injection into a Blood Vessel

Inadvertent intravascular injection is unlikely with a 6 to 8 mm insulin needle in the subcutaneous layer but remains a theoretical risk. If the child experiences sudden dizziness, flushing, or rapid heart rate within 60 seconds of injection, hold pressure at the site and seek immediate evaluation.

Special Considerations by Sub-Age Group

Infants and Toddlers (Under 3 Years)

Subcutaneous fat distribution is different from older children. The anterior thigh is the preferred site in this sub-group, paralleling vaccine administration guidelines from the CDC Advisory Committee on Immunization Practices. [13] Needle depth should not exceed 6 mm. Any TB-500 use in children under 3 is extraordinarily unlikely to have a defensible clinical rationale given the absence of human safety data; if a physician has prescribed it, caregivers should request a written explanation of the specific diagnosis and the evidence base.

Ages 3 to 7

Cooperation with injection can be inconsistent. Use distraction techniques (tablet, song, bubble blowing) that are supported by the American Academy of Pediatrics' procedural pain management recommendations. Never physically restrain a child for a non-emergent injection; the abdominal wall and thigh are still preferred sites. Needle phobia at this age can have long-term procedural effects, and the prescriber should weigh whether the investigational therapy justifies that risk.

Ages 8 to 11

Children in this range can participate in site selection and countdown to injection. Their participation reduces procedural anxiety and gives the caregiver earlier information about pain or unusual sensation. The anterior abdomen and lateral thigh both have adequate subcutaneous tissue in most children by age 8. Teach the child the word for injection discomfort that is normal versus symptoms they should report ("burning that stays after 2 minutes, not the quick pinch").

Storage, Waste Disposal, and Medication Safety at Home

Storage Requirements

• Lyophilized (unreconstituted) vials: store at room temperature, below 25 °C, away from light. Shelf life per manufacturer COA, typically up to 24 months.
• Reconstituted vials: refrigerate at 2 to 8 °C. Use within 30 days. Do not freeze reconstituted solution.
• Keep all vials locked or out of reach of other children in the household.

Safe Disposal

Used syringes and needles go directly into the FDA-cleared sharps container at the point of use. Full sharps containers should be disposed of through a community take-back program. The FDA maintains a directory of safe disposal options at fda.gov. [14] Do not recap needles, do not place loose sharps in household recycling or trash.

Medication Security

Store TB-500 vials separately from other medications to prevent mix-ups. Label the outside of the refrigerator storage bag with the child's name, drug name, concentration, and "KEEP REFRIGERATED. KEEP LOCKED." Children ages 3 to 7 can open standard refrigerator doors; a secondary lock or high shelf matters.

When to Stop and Contact Your Physician

Do not wait for the next scheduled appointment in any of these situations:

• Any two or more injection sites simultaneously show signs of infection.
• The child develops a new rash unrelated to the injection site within 72 hours of a dose.
• The child reports joint pain, unexpected fatigue, or behavioral changes that began after starting TB-500.
• Growth velocity appears to change (parental concern about stature or weight gain should be raised promptly given TB-500's theoretical effects on growth factor pathways).
• The caregiver has any doubt about the dose calculation or reconstitution process for a given vial.

A 2020 pediatric safety framework published in Pediatrics recommended that for any off-label injectable therapy in children, a clear stop-rule and escalation pathway be documented in the medical record before the first dose is administered. [15] Ask your physician to confirm this documentation exists.